Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02200276 · ClinicalTrials.gov registry record · NA
Influenza Immunization in Adults Over Age 75
A NA study of Influenza and Older Adults, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- NA
- Development phase
- 1,025
- Enrollment target
- 1
- Study location
NCT02200276: Recruiting NA study of Influenza and Older Adults, sponsored by Johns Hopkins University.
NCT02200276 is a NA study of Influenza and Older Adults that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 1,025 participants, below the 36,797-participant average among 156 other Influenza trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02200276, a NA study of Influenza and Older Adults, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,025 participants
- Enrollment target
- 1
- Study location
Study Summary
The immune system is the part of the body that protects against infection. The immune system often doesn't work as effectively as people get older. This research is being done to find out how the immune systems in older people who are over age 75 respond to influenza vaccine (flu shot). We also want to find out if chronic cytomegalovirus (CMV) infection, a common virus infection in older persons affects the immune response in people older than 75 years of age who receive a flu shot. The Flu Shot is a vaccine approved for the prevention of influenza ("Flu") infections and is recommended every year for all persons 50 years and older. People who are older than 75 years of age are considered healthy or frail may join. A total of 1025 persons will be participating in this study. In order to determine if you are qualified for the study, we would ask you to answer a few questions over the phone that will take approximately 5 minutes. If you qualify and agree to proceed, you will be asked to come to Johns Hopkins Bayview Medical Center or, if you are unable to come to Bayview, one of our staff can visit you at your home. During that visit we obtain consent, review your medical history, and measure your vital signs, walking speed and grip strength. We will also administer a few brief questionnaires and collect urine and blood samples. We will then give you the Influenza vaccine for free. 7 days post receiving your Influenza Vaccine we will collect a small blood sample for further immune system testing. also, you will be asked to complete a 12-question survey which will assess your symptoms over the past 7 days (post receiving the Influenza vaccine). Also 4 weeks post receiving your Influenza vaccine you will be asked to complete a third visit that will include follow up health questionnaires and an influenza symptoms assessment questionnaire and vital signs. A third blood draw will be collected (approximately 10 teaspoons) to measure immune responses to the influenza vaccin
Primary Outcome
To assess the role of chronic CMV infection as defined by presence of CMV viral DNA in peripheral monocytes as a risk factor for vaccine failure in this oldest old subset.
Conditions Studied
Interventions
- BIOLOGICAL Influenza
Study Locations (1)
Maryland
- Johns Hopkins University; JHAAC 5501 Hopkins Bayview Circle, 1B84 - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,025 participants |
| Start Date | 2014-03 |
| Est. Completion | 2027-11-30 |
| Phase | NA |
What NCT02200276 shows while recruiting
NCT02200276 is an interventional study that assigns participants to a tested intervention. Its 1,025 participants enrollment target places it among the larger protocols in the corpus, below the 36,797-participant average among 156 other Influenza trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Influenza appearing as the primary indexed condition, and to 1 intervention - of which Influenza is the first listed.
NCT02200276 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02200276 about?
NCT02200276 is a clinical study titled "Influenza Immunization in Adults Over Age 75". The immune system is the part of the body that protects against infection. The immune system often doesn't work as effectively as people get older. This research is being done to find out how the immune systems in older people who are over age 75 respond to influenza vaccine (flu shot). We also want...
What is the current status of trial NCT02200276?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,025 participants. The study started on 2014-03. Estimated completion is 2027-11-30.
What conditions does trial NCT02200276 study?
This clinical trial studies the following conditions: Influenza, Older Adults, Immunization, Over Age 75.
What interventions are being tested in trial NCT02200276?
The interventions under investigation include: Influenza (BIOLOGICAL).
Who is sponsoring clinical trial NCT02200276?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02200276 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02200276's enrollment target sits among peer trials
1,025 35th of 156 higher than 122 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
H5N1 Milk Detection Study
RECRUITING · NA
-
Immune Defense Protein Impact On Respiratory Immune Outcomes
RECRUITING · NA
-
Dime La VerDAD: Verify, Debunk, and Disseminate
RECRUITING · NA
-
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
RECRUITING · NA
-
Impact of High Dietary Fiber on Microbiome and Vaccine Responses
ACTIVE NOT RECRUITING · NA
-
Exercise and COVID-19 Viral T-cell Immunity
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02296450 · 1,025 participants
Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments
- NCT06888011 · 1,024 participants · NA
iAmHealthy Clinical Practice Guideline (CPG)
- NCT07216703 · 1,023 participants · Phase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- NCT06080698 · 1,030 participants · NA
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia